(Q79318184)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

8

Jaffer A Ajani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Pooja R Rohatgi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

James C Yao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Kenneth Hess

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Isac Schnirer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Asif Rashid

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Paul F Mansfield

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Peter W Pisters

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

1 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

2576-2580

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Evolving chemotherapy for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Cancer of the stomach. A patient care study by the American College of Surgeons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Treatment of localized gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Pathological features as predictors of recurrence after radical resection of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Perspectives in the treatment of gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Results of chemoirradiation after curative resection of locally advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Survival after surgical treatment of early gastric cancer, surgical techniques, and long-term survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Extended lymph-node dissection for gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Survival benefit of D2 lympadenectomy in patients with gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22317

7 January 2021

Identifiers

DOI

10.1002/CNCR.22317

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17075877%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference